Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain

Plain-language guide to NCT07532876: phase 4 non-randomized trial of Elagolix (non-peptide), endometriosis, 90 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT07532876
Phase: phase 4
Status: enrolling by invitation
Start: 2026-05-01
Completion (planned or actual): 2026-10-01
Participants: 90 (estimated)
Design: non-randomized, open label (everyone knows who gets what), treatment
Conditions studied: Endometriosis (Diagnosis)
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

In this phase 4 trial, researchers set out to test Elagolix (non-peptide) for endometriosis.

It had two arms (groups): Elagolix Group (experimental) and OCPs group (experimental).

45 Participants in this group. OCPs will be administered once daily in a continuous 28-day cycles for 3 months.

The registry classes the interventions as drug.

More on the Plan

Baseline demographic and clinical information will be recorded.

Pain outcomes (dysmenorrhea, dyspareunia, non menstrual pain) will be assessed on the NRS at baseline, 12 weeks, and 24 weeks.

Adverse events will be documented throughout.

Who Took Part

Enrollment: 90 planned participants were the target.

It was open to women only aged from 18 years up to 45 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Women aged 18-45 years. Clinically or surgically confirmed endometriosis. Having regular menstrual cycles. Willingness to participate with informed consent.

The full record lists 4 inclusion and 2 exclusion criteria; among the exclusions: contraindications to ocps (e.g., thromboembolism, cardiovascular disease, uncontrolled hypertension, smoking over age 35); contraindications to elagolix (e.g., osteoporosis, pregnancy, hypersensitivity, severe depression) prior hysterectomy or bilateral oophorectomy, other identifiable causes of pelvic pain.

How the Study Was Run

The set-up was non-randomized, parallel-group and open-label.

The Elagolix (non-peptide) group and the comparison group ran side by side rather than switching.

Being open-label, the Elagolix (non-peptide) study did not mask who received what.

It started in 2026-05-01 with completion listed for 2026-10-01.

It ran at 1 site in Pakistan.

Its stated primary purpose is treatment.

What This Means in Plain Language

Put simply, this is a phase 4, non-randomized trial of Elagolix (non-peptide) in 90 people with endometriosis.

Its status is enrolling by invitation; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Elagolix (non-peptide) compound page, Endometriosis research.

Our Notes on the Compound

Elagolix (non-peptide): An oral non-peptide GnRH antagonist (Orilissa) approved for endometriosis pain; combined with add-back hormones (Oriahnn) for fibroid bleeding.

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.